A Multi-Centre, Single Arm, Phase 2 Trial of Pembrolizumab in Treatment Naïve Patients With Poor-Prognosis Carcinoma of Unknown Primary Site
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Aug 2018 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 Planned initiation date changed from 15 Jan 2018 to 1 Apr 2018.
- 09 Jan 2018 New trial record